Abstract
In dermatological diagnosis, accurately and appropriately classifying skin diseases is crucial for timely treatment, thereby improving patient outcomes. Our goal is to develop transfer learning models that can detect skin disease from images. We performed our study in the “Skin Cancer: MNIST HAM10000” dataset. This dataset has seven categories, including melanocytic nevi, melanoma, benign keratosis (solar lentigo/seborrheic keratosis), basal cell carcinoma, actinic keratoses, intraepithelial carcinoma (Bowen’s disease), vascular lesions, and more. To leverage pre-trained feature extraction, we use five available models—ResNet50, InceptionV3, VGG16, VGG19, and MobileNetV2. Overall results from these models show that ResNet50 is the least time-intensive and has the best accuracy (99%) in comparison to other classification performances. Interestingly, with a notable accuracy of 97.5%, MobileNetV2 also seems to be adequate in scenarios with less computational power than ResNet50. Finally, to interpret our black box model, we have used LIME as an explainable AI technique (XAI) to identify how the model is classifying the disease. The results emphasize the utility of transfer learning for optimizing diagnostic accuracy in skin disease classification, blending performance and resource efficiency as desired. The findings from this study may contribute to the development of automated tools for dermatological diagnosis and enable clinicians to reduce skin conditions in a timely manner.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.